Lewes, DE -- (SBWire) -- 11/10/2015 --This segment includes only the analyzers and reagents used in core labs of hospitals and in independent commercial labs, without taking into consideration the point-of-care (POC) equipment. The U.S. hemostasis testing is a well-established market, with nearly every hospital and reference lab having an analyzer, and most large hospitals having a backup unit in addition to their primary analyzer. The matured nature of the market and high installed base has led to relatively stable annual unit sales, with replacement of the older machines accounting for a majority of the total sales.
Routine high volume tests such as prothrombin time (PT), thrombin time (TT), activated partial thromboplastin time (APTT) and D-dimer account for more than 65% of the total hemostasis tests. Tests for monitoring anticoagulant therapies are expected to decrease as new anticoagulant drugs that do not require monitoring are expected to enter the market. Aging population and the inclusion of millions of people into the health insurance bracket due to the Affordable Care Act (ACA) will create increased demand for routine hemostasis tests. However, transitioning to outcome-based reimbursements model from fee-for-service model, due to the emergence of accountable care organizations (ACOs), will increase POC testing volumes, thus driving down the volumes and cost per test at both core lab sites and reference labs.
The competitive analysis outlines Siemens Healthcare Diagnostics as a leader in this market segment, but with Instrumentation Laboratory and other close behind.
This Report includes extensive detail on:
- Hemostasis Analyzer Market
- Hemostasis Reagent Market
This Report Also Includes:
- In-depth, Professionally Researched Data That Has Been Formatted and Analyzed to Gain Actionable Insights as Quickly as Possible
Executive Summary
- Trend Analysis by Segment
- Market Value Forecasts until 2022 and History Back to 2012
- Market Drivers and Limiters
- Detailed Competitive Analysis for Each Market and Segment
To Get The Most Out Of This Report:
Combine it with our other US market reports on, Hematology, Immunochemistry, Molecular Diagnostics, Blood Donor Screening, or Point of Care Diagnostic Devices.
Routine high volume tests such as prothrombin time (PT), thrombin time (TT), activated partial thromboplastin time (APTT) and D-dimer account for more than 65% of the total hemostasis tests. Tests for monitoring anticoagulant therapies are expected to decrease as new anticoagulant drugs that do not require monitoring are expected to enter the market.
Spanning over 48 pages "US Market for Hemostasis Devices - 2016 (Forecasted to 2022)" report covers Executive Summary, Research Methodology, Hemostasis Market. The report covered companies are - Siemens Healthcare Diagnostics, Instrumentation Laboratory, Diagnostica Stago, Bio/Data Corporation, Chrono-Log Corporation, Thermo Scientific
For further information on this report, please visit- http://www.marketresearchreports.com/idata-research/us-market-hemostasis-devices-2016-forecasted-2022
Find all Medical Devices Reports at: http://www.marketresearchreports.com/medical-devices
About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.
Yearly/Quarterly Report Subscription: http://www.marketresearchreports.com/subscriptions
